Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Mizuho

Mizuho Expects EV Stocks Like Nio, Tesla, Rivian Set To Gain - Here's How

Mizuho analyst Vijay Rakesh sees BEV (Battery electric vehicle) as a bright spot amid macro headwinds led by China rebounding.

Benzinga

Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data

The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time.

Benzinga

Here's How Mizuho Views AMD, Nvidia, Qualcomm

Mizuho analyst Vijay Rakesh included Gigabyte, a distributor of GPUs and a motherboard OEM, and Zhen Ding, a leading PCB supplier in coverage post-Asia tech series checks.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Read Why Mizuho Re-rated Adobe Ahead Of Its 2Q Earnings

Adobe Inc (NASDAQ: ADBE) will report its 2Q results on June 16, Mizuho analyst Gregg Moskowitz noted.

Benzinga

10 Biggest Price Target Changes For Friday

Mizuho cut Adobe Inc. (NASDAQ: ADBE) price target from $600 to $530. Adobe shares fell 1.1% to $421.77 in pre-market trading.

Benzinga

Mizuho's Bullish Re-Rating On PayPal Had An Apple Connection - Read To Know

Mizuho analyst Dan Dolev's proprietary survey of PayPal Holdings, Inc's (NASDAQ:PYPL) Venmo and Apple Inc (NASDAQ:AAPL) Apple Pay exhibited a "strong appetite" to tap to pay with Venmo if Apple opened up its near field communication to Venmo. Dolev estimates that tap-to-pay with Venmo could present a 10% total payment volume and 15%-20% sales upside given Venmo's…

Benzinga

Here's How Analysts Reacted To Microsoft's Outlook Revision

Microsoft Corp (NASDAQ:MSFT) updated its Q4 and FY23 guidance due to recent unfavorable currency headwinds. Microsoft cited an incremental $460 million headwind from FX to its total revenue guidance issued in late April, representing slightly less than a 100bps delta on total revenue. Microsoft now expects revenue of $51.94 billion - $52.74 billion…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

5 CrowdStrike Analysts React To Q1 Earnings Beat, Guidance Hike, Potential Hiring Ramp

CrowdStrike Holdings Inc (NASDAQ: CRWD) shares traded down by 6.2% on Friday after the company reported a first-quarter earnings beat and raised its full-year guidance.

Benzinga

Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness

Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT for psychosis in Alzheimer's disease.

Benzinga

Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock

Mizuho remains bullish on Arcutis Biotherapeutics Inc (NASDAQ: ARQT). It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for ARQT.

Benzinga

Why Did Mizuho Cut Price Target On This CAR-T Stock, But Remain Bullish

Mizuho met Cabaletta Bio Inc (NASDAQ: CABA) management team after last week's data release at ASGCT.

Benzinga

Here's Why Mizuho Remains Incrementally Positive On Uber, Meta, Baidu, JD

Mizuho analyst James Lee recently met with investors and discussed U.S. and China internet coverage. With concerns about U.S. consumer demand and economic outlook, Lee senses that sentiment on China's Internet is improving.

Benzinga

The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial. Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)…

Benzinga

Check Out What Whales Are Doing With COIN

Someone with a lot of money to spend has taken a bearish stance on Coinbase Global (NASDAQ:COIN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Mizuho Remains Bullish On JD Post Q1 - Read Why

Mizuho analyst James Lee maintained a Buy on JD.com, Inc (NASDAQ:JD) with a price target of $90 (75% upside). JD beat top line and margins due to its competitive advantage in supply chain and logistics, which enabled the company to gain share. The COVID lockdown impact in 2Q22 was more than Lee's expectation at 5% YoY growth,…

Benzinga

Coinbase Global Whale Trades For May 18

Benzinga

Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences

RBC Capital writes that Wave Life Sciences Ltd's (NASDAQ: WVE) Q1 earnings are largely incremental.

Benzinga

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Mizuho Remains Bullish On This Small-Cap Stock's Migraine Candidate, But Why Did It Cut Price Target

Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal dihydroergotamine (DHE) for migraine.

Benzinga

Jack Dorsey's Block Would Shine If It Wasn't For Bitcoin Holding It Back, Says Analyst

Equity research analysts from Mizuho believe that Jack Dorsey’s payments firm Block Inc (NASDAQ: SQ) should downplay its association with Bitcoin (CRYPTO:

Benzinga

Why These Beyond Meat Analysts Are Barbecuing Price Targets After $100M Q1 Loss: 'Lower Likelihood Of Disruption'

Beyond Meat Inc (NASDAQ: BYND) shares traded higher Thursday before moving lower in the afternoon, and remain down 56.6% year-to-date after the company reported a larger-than-expected first-quarter net lo

Benzinga

Coinbase Global Whale Trades For May 06

A whale with a lot of money to spend has taken a noticeably bearish stance on Coinbase Global. Looking at options history for Coinbase Global (NASDAQ:COIN) we detected 44 strange trades.

Benzinga

Mizuho Maintains Buy Rating for Avalara: Here's What You Need To Know

Mizuho has decided to maintain its Buy rating of Avalara (NYSE:AVLR) and lower its price target from $160.00 to $110.00. Shares of Avalara are trading up 8.77% over the last 24 hours, at $76.12 per share. A move to $110.00 would account for a 44.51% increase from the current share…

Benzinga

Mizuho Maintains Buy Rating for Enterprise Prods Partners: Here's What You Need To Know

Mizuho has decided to maintain its Buy rating of Enterprise Prods Partners (NYSE:EPD) and raise its price target from $30.00 to $32.00. Shares of Enterprise Prods Partners are trading up 2.28% over the last 24 hours, at $26.20 per share.

Benzinga

Mizuho Continues To See Upside In Alibaba, JD, Baidu, Dada Amid Odds

Mizuho saw a challenging 1H22 for China's internet, given the ongoing disruptions to consumer spending and business activities from COVID restrictions. Mizuho expects the negative impact to spread across all internet segments, including e-commerce, advertising, and cloud computing.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.